195 related articles for article (PubMed ID: 34208189)
1. Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4
Cano-Garrido O; Álamo P; Sánchez-García L; Falgàs A; Sánchez-Chardi A; Serna N; Parladé E; Unzueta U; Roldán M; Voltà-Durán E; Casanova I; Villaverde A; Mangues R; Vázquez E
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208189
[TBL] [Abstract][Full Text] [Related]
2. Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4
Sala R; Sánchez-García L; Serna N; Céspedes MV; Casanova I; Roldán M; Sánchez-Chardi A; Unzueta U; Vázquez E; Mangues R; Villaverde A
Acta Biomater; 2019 Nov; 99():426-432. PubMed ID: 31494293
[TBL] [Abstract][Full Text] [Related]
3. Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.
Unzueta U; Céspedes MV; Ferrer-Miralles N; Casanova I; Cedano J; Corchero JL; Domingo-Espín J; Villaverde A; Mangues R; Vázquez E
Int J Nanomedicine; 2012; 7():4533-44. PubMed ID: 22923991
[TBL] [Abstract][Full Text] [Related]
4. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; Mangues R; Alba-Castellón L; León X
Acta Pharm Sin B; 2022 May; 12(5):2578-2591. PubMed ID: 35646535
[TBL] [Abstract][Full Text] [Related]
5. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
[TBL] [Abstract][Full Text] [Related]
6. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
7. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
9. LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells.
Wang RT; Zhi XY; Yao SY; Zhang Y
Colloids Surf B Biointerfaces; 2015 Sep; 133():43-50. PubMed ID: 26070050
[TBL] [Abstract][Full Text] [Related]
10. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
11. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
12. Selective CXCR4
Díaz R; Pallarès V; Cano-Garrido O; Serna N; Sánchez-García L; Falgàs A; Pesarrodona M; Unzueta U; Sánchez-Chardi A; Sánchez JM; Casanova I; Vázquez E; Mangues R; Villaverde A
Small; 2018 Jun; 14(26):e1800665. PubMed ID: 29845742
[TBL] [Abstract][Full Text] [Related]
13. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4.
Serna N; Carratalá JV; Conchillo-Solé O; Martínez-Torró C; Unzueta U; Mangues R; Ferrer-Miralles N; Daura X; Vázquez E; Villaverde A
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834337
[TBL] [Abstract][Full Text] [Related]
15. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
16. Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.
Álamo P; Pallarès V; Céspedes MV; Falgàs A; Sanchez JM; Serna N; Sánchez-García L; Voltà-Duràn E; Morris GA; Sánchez-Chardi A; Casanova I; Mangues R; Vazquez E; Villaverde A; Unzueta U
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105866
[TBL] [Abstract][Full Text] [Related]
17. The two human CXCR4 isoforms display different HIV receptor activities: consequences for the emergence of X4 strains.
Duquenne C; Psomas C; Gimenez S; Guigues A; Carles MJ; Barbuat C; Lavigne JP; Sotto A; Reynes J; Guglielmi P; Mettling C; François V; Corbeau P
J Immunol; 2014 Oct; 193(8):4188-94. PubMed ID: 25230750
[TBL] [Abstract][Full Text] [Related]
18. Targeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem Cells.
Jiang X; Wang C; Fitch S; Yang F
Theranostics; 2018; 8(5):1350-1360. PubMed ID: 29507625
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
20. Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles.
Serna N; Sánchez JM; Unzueta U; Sánchez-García L; Sánchez-Chardi A; Mangues R; Vázquez E; Villaverde A
Nanotechnology; 2019 Mar; 30(11):115101. PubMed ID: 30561375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]